Yvan Beaussant

Yvan Beaussant

Auto-generated profile, based on publicly available information

Yvan Beaussant

Department of Supportive Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2023 in Cancer
Verified
Journal Article
Closed access
MAManish Agrawal
Manish Agrawal
WRWilliam Richards
William Richards
YBYvan Beaussant
Yvan Beaussant
SSSarah Shnayder
Sarah Shnayder
RARezvan Ameli
Rezvan Ameli
PTPaul Thambi
Paul Thambi

11 February 2022 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
LMLucas Oliveira Maia
Lucas Oliveira Maia
YBYvan Beaussant
Yvan Beaussant
Ana Cláudia Mesquita GarciaAna Cláudia Mesquita Garcia
Ana Cláudia Mesquita Garcia

22 September 2020 in Journal of Palliative Medicine
Verified
Journal Article
Closed access
YBYvan Beaussant
Yvan Beaussant
JSJustin Sanders
Justin Sanders
ZSZachary Sager
Zachary Sager
JTJames A. Tulsky
James A. Tulsky
IBIlana M. Braun
Ilana M. Braun
IBIra Byock
Ira Byock
Background: Recent and preprohibition studies show that patients with serious illness might benefit from psychedelic-assisted therapies for a range of symptoms, physical, psychosocial, and existential. Objective: To explore the potential roles and research priorities of these therapies in patients with serious illness. Design, Setting, and Participants: Qualitative study based on semistructured interviews with 17 experts in serious illness care and/or psychedelic research from the United States and Canada. Measurements: The interview guide elicited participants' perspectives on (1) the potential roles of psychedelic-assisted therapies in this setting, (2) research priorities relevant to this population, and (3) the potential for integrating psychedelic-assisted therapies into existing delivery models of serious illness care. We used thematic analysis until thematic saturation. Results: Domain I: Participants had polar views on the therapeutic potential of psychedelic-assisted therapies, ranging from strong beliefs in their medical utility to reluctance about their use in this patient population. They shared concerns related to the risks of adverse effects, such as delirium or worsening of psychological distress. Domain II: Research priorities primarily concerned patients with clinically diagnosed psychosocial distress, such as depression, anxiety, or demoralization. Participants also articulated potential roles extending beyond traditional medical diagnosis. Domain III: Participants emphasized essential safety and efficacy guidelines relevant to the integration of these therapies into existing models of care. Conclusion: This qualitative study highlights issues and priorities for research on psychedelic-assisted therapies in patients with serious illness and proposes a conceptual framework for integrating these therapies into existing delivery models of serious illness care.

1 November 2021 in Journal of Palliative Medicine
Verified
Journal Article
Closed access
YBYvan Beaussant
Yvan Beaussant
JTJames Tulsky
James Tulsky
BGBenjamin Guérin
Benjamin Guérin
CSClaudia Schwarz-Plaschg
Claudia Schwarz-Plaschg
JSJustin J. Sanders
Justin J. Sanders
Background: With support from the Radcliffe Institute for Advanced Study at Harvard University, we convened researchers representing palliative care, psychosocial oncology, spiritual care, oncology, and psychedelic-assisted therapies. We aimed to define priorities and envision an agenda for future research on psychedelic-assisted therapies in patients with serious illness. Over two days in January 2020, participants engaged in an iterative series of reflective exercises that elicited their attitude and perspectives on scientific opportunities for this research. Objectives: The aim of the study is to identify themes that shape priorities and an agenda for research on psychedelic-assisted therapy for those affected by serious illness. Methods: We collected data through preconference interviews, audio recordings, flip charts, and sticky notes. We applied thematic qualitative analysis to elucidate key themes. Results: We identified seven key opportunities to advance the field of psychedelic-assisted therapies in serious illness care. Four opportunities were related to the science and design of psychedelic-assisted therapies: clarifying indications; developing and refining therapeutic protocols; investigating the impact of set and setting on therapeutic outcomes; and understanding the mechanisms of action. The other three pertained to institutional and societal drivers to support optimal and responsible research: education and certification for therapists; regulations and funding; and diversity and inclusion. Additionally, participants suggested epistemological limitations of the medical model to understand the potential value and therapeutic use of psychedelics. Conclusions: Medicine and society are witnessing a resurgence of interest in the effects and applications of psychedelic-assisted therapies in a wide range of settings. This article suggests key opportunities for research in psychedelic-assisted therapies for those affected by serious illness.

18 December 2023 in Cancer
Verified
Journal Article
Closed access
YBYvan Beaussant
Yvan Beaussant
ETElise C Tarbi
Elise C Tarbi
KNKabir Nigam
Kabir Nigam
SMSkye Miner
Skye Miner
ZSZachary Sager
Zachary Sager
MAManish Agrawal
Manish Agrawal

26 July 2016 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
PDF file
LMLucas Morin
Lucas Morin
YBYvan Beaussant
Yvan Beaussant
RARégis Aubry
Régis Aubry
JFJohan Fastbom
Johan Fastbom
KJKristina Johnell
Kristina Johnell